ARS Pharmaceuticals, Inc. (SPRY) Current Ratio
- Current ratio · latest quarter: Value 3.48×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.48× | Current assets / current liabilities. $211.51M ÷ $60.86M ≈ 3.48× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 211.51M USD | Assets, Current |
| Current obligations | 60.86M USD | Liabilities, Current |
| Cash and equivalents | 8.16M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 46.84M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 30.73M USD | Inventory, Net |
| Payables | 5.20M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $211.51M | $60.86M | $8.16M | (m) | $46.84M | $30.73M | $5.20M | (m) | 3.48× |
| 2026-03-31 | $245.24M | $49.61M | $24.32M | (m) | $28.66M | $32.04M | $4.71M | (m) | 4.94× |
| 2025-12-31 | $284.90M | $39.15M | $41.32M | (m) | $25.35M | $31.42M | $5.72M | (m) | 7.28× |
| 2025-09-30 | $338.86M | $50.88M | $59.56M | (m) | $36.45M | $21.43M | $8.38M | (m) | 6.66× |
| 2025-06-30 | $281.44M | $45.60M | $51.54M | (m) | $25.13M | $22.11M | $15.56M | (m) | 6.17× |
| 2025-03-31 | $303.86M | $27.62M | $39.86M | (m) | $9.30M | $7.27M | $4.09M | (m) | 11.00× |
| 2024-12-31 | $334.30M | $23.44M | $50.82M | (m) | $8.18M | $10.52M | $9.87M | (m) | 14.26× |
| 2024-09-30 | $208.79M | $16.62M | $39.66M | (m) | $773.00K | $715.00K | $8.28M | (m) | 12.56× |
| 2024-06-30 | $220.74M | $6.72M | $36.63M | (m) | (m) | (m) | $3.27M | (m) | 32.82× |
| 2024-03-31 | $226.24M | $3.71M | $56.01M | (m) | (m) | (m) | $839.00K | (m) | 60.90× |
| 2023-12-31 | $231.73M | $2.39M | $70.97M | (m) | $0.00 | $0.00 | $759.00K | (m) | 96.92× |
| 2023-09-30 | $244.47M | $11.18M | $60.53M | (m) | (m) | (m) | $2.97M | (m) | 21.87× |
| 2023-06-30 | $255.03M | $10.05M | $119.02M | (m) | (m) | (m) | $1.50M | (m) | 25.37× |
| 2023-03-31 | $267.35M | $9.84M | $87.86M | (m) | (m) | (m) | $2.58M | (m) | 27.18× |
| 2022-12-31 | $277.70M | $5.44M | $210.52M | (m) | (m) | (m) | $1.66M | (m) | 51.01× |
| 2022-09-30 | $270.80M | $3.99M | $203.22M | (m) | (m) | (m) | $126.00K | (m) | 67.87× |
| 2022-06-30 | $263.13M | $11.14M | $218.69M | (m) | (m) | (m) | $2.11M | (m) | 23.61× |
| 2022-03-31 | $261.33M | $14.81M | $233.99M | (m) | (m) | (m) | $2.63M | (m) | 17.65× |
| 2021-12-31 | $60.73M | $8.19M | $60.06M | (m) | (m) | (m) | $1.79M | (m) | 7.42× |
| 2021-09-30 | $305.36M | $15.35M | $300.66M | (m) | (m) | (m) | $1.72M | (m) | 19.90× |
| 2021-06-30 | $363.03M | $15.55M | $359.69M | (m) | (m) | (m) | $1.80M | (m) | 23.35× |
| 2021-03-31 | $378.35M | $11.60M | $374.20M | (m) | (m) | (m) | $4.37M | (m) | 32.63× |
| 2020-12-31 | $390.66M | $9.60M | $386.57M | (m) | (m) | (m) | $2.58M | (m) | 40.69× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |